Vertex Pharmaceuticals
Company Overview
Keywords
Description
Vertex Pharmaceuticals is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has made significant advancements in multiple chronic, life-shortening genetic diseases such as cystic fibrosis, sickle cell disease, and transfusion-dependent beta thalassemia. Vertex continues to progress clinical and research programs in these diseases. They also have a robust clinical pipeline of investigational therapies across various modalities in other serious diseases where they have deep insight into causal human biology, including acute and neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes, myotonic dystrophy type 1, and alpha-1 antitrypsin deficiency. Vertex's global headquarters is in Boston, with research and development (R&D) sites and commercial offices worldwide. The company is consistently recognized as one of the industry’s top places to work by Science Magazine, The Boston Globe, Boston Business Journal, and the San Diego Business Journal. Vertex has also earned a spot on TIME Most Influential Companies, TIME Best Inventions, and Fast Company Most Innovative Companies lists. Their research and medicines have received esteemed recognitions, including the Robert J. Beall Therapeutics Development Award, the Prix Galien, the Scrip Award, and the Breakthrough Prize awards. For more information, please read their community guidelines: https://www.vrtx.com/vertexs-community-guidelines/
Funding History
| Date | Round | Amount | Lead Investors |
|---|---|---|---|
| Jul 10, 2024 | Post-IPO Secondary | $1,111,135 | N/A |
| May 17, 2022 | Post-IPO Equity | $50,000,000 | N/A |
| Dec 3, 2009 | Post-IPO Equity | $443,000,000 | N/A |
| Sep 30, 2009 | Post-IPO Debt | $120,000,000 | N/A |
| Sep 30, 2009 | Post-IPO Equity | $35,000,000 | Janssen Belgium |
| Mar 17, 2009 | Post-IPO Equity | $2,397,225 | N/A |
| Jul 17, 1989 | Venture Round | $5,800,000 | N/A |
Technology Stack
+372 more technologies
Key Employees
View AllFind Executive job changes at Vertex Pharmaceuticals
Frequently Asked Questions
Employee Statistics
By Seniority
Key People
Julie H
Vice President Research + Manufacturing Technology
Boston, Massachusetts
Alex A
Executive Director and Head of Data Science
Boston, Massachusetts
Greg R
Senior Director , Commercial Information Technology
Boston, Massachusetts
Manasi M
Vice President Vertex , Chief Medical Officer Viacyte
San Diego, California
Benjamin B
Director , Digital Process Automation
Boston, Massachusetts
Similar Companies
Biogen
Business Services
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities, to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth. With approximately 7,000 people worldwide, we are truly a global organization, headquartered in Cambridge, Massachusetts, which is also home to our research operations. Our international headquarters are based in Baar, Switzerland and we have world-class manufacturing facilities in North Carolina and Solothurn, Switzerland. We offer therapies globally through direct affiliate presence in 30 countries and a network of distribution partners in over 50 additional countries. For more information, please visit www.biogen.com. Community Guidelines: https://www.biogen.com/community-guidelines.html Follow us on social media – LinkedIn, Facebook, X, and YouTube.
Waters Corporation
Business Services
Waters Corporation (NYSE: WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, food, and environmental sciences for more than 60 years. With more than 7,800 employees worldwide, Waters operates directly in 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries. Learn more at www.waters.com.
Bruker
Business Services
Right from the beginning, more than sixty years ago, Bruker has been driven by a single idea: to provide the best technological solution for each analytical task. Today, worldwide, more than 9,700 employees in over 90 locations on all continents are focusing their efforts on this permanent challenge. Bruker systems cover a broad spectrum of applications in all fields of research and development and are used in all industrial production processes for the purpose of ensuring quality and process reliability. Bruker continues to build upon its extensive range of products and solutions, expand its broad base of installed systems, and maintain a strong reputation amongst its customers. As one of the world's leading analytical instrumentation companies, Bruker remains focused on developing state-of-the-art technologies and innovative solutions for today’s ever-complex analytical questions. Bruker - Innovation with Integrity. Privacy Policy: https://goto.bruker.com/LI-Bruker-PrivacyPolicy Imprint: Bruker Corporation 40 Manning Road Billerica, MA 01821, USA Contacts: - Phone: +1 978-663-3660 - Fax: +1 978-663-5585 - Email: pr@bruker.com